These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 25002850)

  • 1. Metabolic and hormonal signatures in pre-manifest and manifest Huntington's disease patients.
    Wang R; Ross CA; Cai H; Cong WN; Daimon CM; Carlson OD; Egan JM; Siddiqui S; Maudsley S; Martin B
    Front Physiol; 2014; 5():231. PubMed ID: 25002850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease.
    Leoni V; Mariotti C; Tabrizi SJ; Valenza M; Wild EJ; Henley SM; Hobbs NZ; Mandelli ML; Grisoli M; Björkhem I; Cattaneo E; Di Donato S
    Brain; 2008 Nov; 131(Pt 11):2851-9. PubMed ID: 18772220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver function in Huntington's disease assessed by blood biochemical analyses in a clinical setting.
    Nielsen SM; Vinther-Jensen T; Nielsen JE; Nørremølle A; Hasholt L; Hjermind LE; Josefsen K
    J Neurol Sci; 2016 Mar; 362():326-32. PubMed ID: 26944172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease.
    Popovic V; Svetel M; Djurovic M; Petrovic S; Doknic M; Pekic S; Miljic D; Milic N; Glodic J; Dieguez C; Casanueva FF; Kostic V
    Eur J Endocrinol; 2004 Oct; 151(4):451-5. PubMed ID: 15476444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in the metabolic and cardiorespiratory response to exercise in Huntington's Disease.
    Steventon JJ; Collett J; Furby H; Hamana K; Foster C; O'Callaghan P; Dennis A; Armstrong R; Németh AH; Rosser AE; Murphy K; Quinn L; Busse M; Dawes H
    Parkinsonism Relat Disord; 2018 Sep; 54():56-61. PubMed ID: 29705557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Language disintegration in spontaneous speech in Huntington's disease: a more fine-grained analysis.
    Tovar A; Garí Soler A; Ruiz-Idiago J; Mareca Viladrich C; Pomarol-Clotet E; Rosselló J; Hinzen W
    J Commun Disord; 2020; 83():105970. PubMed ID: 32062158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prefrontal executive function associated coupling relates to Huntington's disease stage.
    Unschuld PG; Liu X; Shanahan M; Margolis RL; Bassett SS; Brandt J; Schretlen DJ; Redgrave GW; Hua J; Hock C; Reading SA; van Zijl PC; Pekar JJ; Ross CA
    Cortex; 2013; 49(10):2661-73. PubMed ID: 23906595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Influencing the Total Functional Capacity Score as a Critical Endpoint in Huntington's Disease Research.
    Achenbach J; Stodt B; Saft C
    Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137557
    [No Abstract]   [Full Text] [Related]  

  • 9. Altered brain mechanisms of emotion processing in pre-manifest Huntington's disease.
    Novak MJ; Warren JD; Henley SM; Draganski B; Frackowiak RS; Tabrizi SJ
    Brain; 2012 Apr; 135(Pt 4):1165-79. PubMed ID: 22505631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ghrelin-mediated improvements in the metabolic phenotype in the R6/2 mouse model of Huntington's disease.
    Rudenko O; Springer C; Skov LJ; Madsen AN; Hasholt L; Nørremølle A; Holst B
    J Neuroendocrinol; 2019 Jul; 31(7):e12699. PubMed ID: 30776164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
    Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life in Huntington's disease: a comparative study investigating the impact for those with pre-manifest and early manifest disease, and their partners.
    Read J; Jones R; Owen G; Leavitt BR; Coleman A; Roos RA; Dumas EM; Durr A; Justo D; Say M; Stout JC; Tabrizi SJ; Craufurd D;
    J Huntingtons Dis; 2013; 2(2):159-75. PubMed ID: 25063513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered frontostriatal coupling in pre-manifest Huntington's disease: effects of increasing cognitive load.
    Wolf RC; Sambataro F; Vasic N; Schönfeldt-Lecuona C; Ecker D; Landwehrmeyer B
    Eur J Neurol; 2008 Nov; 15(11):1180-90. PubMed ID: 18754766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variability in interval production is due to timing-dependent deficits in Huntington's disease.
    Rao AK; Marder KS; Uddin J; Rakitin BC
    Mov Disord; 2014 Oct; 29(12):1516-22. PubMed ID: 25154339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autonomic symptoms in patients and pre-manifest mutation carriers of Huntington's disease.
    Aziz NA; Anguelova GV; Marinus J; van Dijk JG; Roos RA
    Eur J Neurol; 2010 Aug; 17(8):1068-74. PubMed ID: 20192977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 24-Hour Study of the Hypothalamo-Pituitary Axes in Huntington's Disease.
    Kalliolia E; Silajdžić E; Nambron R; Costelloe SJ; Martin NG; Hill NR; Frost C; Watt HC; Hindmarsh P; Björkqvist M; Warner TT
    PLoS One; 2015; 10(10):e0138848. PubMed ID: 26431314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in cognitive control in pre-manifest Huntington's disease examined using pre-saccadic EEG potentials - a longitudinal study.
    Ness V; Bestgen AK; Saft C; Beste C
    J Huntingtons Dis; 2014; 3(1):33-43. PubMed ID: 25062763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study.
    Paulsen JS; Long JD; Ross CA; Harrington DL; Erwin CJ; Williams JK; Westervelt HJ; Johnson HJ; Aylward EH; Zhang Y; Bockholt HJ; Barker RA;
    Lancet Neurol; 2014 Dec; 13(12):1193-201. PubMed ID: 25453459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uric Acid as a Potential Peripheral Biomarker for Disease Features in Huntington's Patients.
    Corey-Bloom J; Haque A; Aboufadel S; Snell C; Fischer RS; Granger SW; Granger DA; Thomas EA
    Front Neurosci; 2020; 14():73. PubMed ID: 32194366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emotion recognition and inhibitory control in manifest and pre-manifest Huntington's disease: evidence from a new Stroop task.
    Hunefeldt T; Maffi S; Migliore S; Squitieri F; Belardinelli MO
    Neural Regen Res; 2020 Aug; 15(8):1518-1525. PubMed ID: 31997817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.